A Phase 3 interventional study of Placebo and Tocilizumab in COVID-19 Pneumonia, sponsored by Genentech, Inc.. Completed at 44 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-10.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing tocilizumab in COVID-19 — 3 open to participants now, 4 under way, 2 of them phase 3. tocilizumab · COVID-19.
Among the 38 studies testing tocilizumab in COVID-19, this one is the 9th largest by enrollment, is one of 34 that started in 2020, is one of 13 in phase 3, and was the 18th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →3 of the 38 studies testing tocilizumab in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Lebanese University · Sites in Lebanon
Ages 18+
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 14 · Phase 4 2
First in 2016; this study’s year is marked. 34 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 377 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 150 across the 38 interventional studies. Of the 23 that completed or were terminated, 8 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
Hoffmann-La Roche has 9 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 38 studies testing tocilizumab in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study (EMPACTA) will a) evaluate the efficacy and safety of tocilizumab (TCZ) compared with a placebo in combination with standard of care (SOC) in hospitalized participants with COVID-19 pneumonia, and b) include an optional long-term extension for eligible participants to explore the long-term sequelae of resolved COVID-19 pneumonia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria Specific to Long-Term Extension
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one intravenous (IV) infusion of placebo, in addition to SOC. Up to one additional infusion may be given.
Drug: Placebo
Participants will receive one IV infusion of TCZ in addition to SOC. Up to one additional infusion may be given.
Drug: Tocilizumab
Participants will receive one dose of IV placebo matched to TCZ. Up to one additional dose may be given.
Participants will receive one IV infusion of TCZ 8 mg/kg, with a maximum dose of 800 mg. Up to one additional dose may be given.
Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28
Cumulative proportion is measured as a percentage of participants meeting the endpoint.
Time frame: Up to Day 28
Time to Hospital Discharge or "Ready for Discharge" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or >/= 2 Liters (L) Supplemental Oxygen)
Time frame: Up to Day 28
Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status
Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</=2 liters supplemental oxygen) 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death
Time frame: Up to Day 28
Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (Whichever Occurred First)
Time frame: Up to Day 28
Mortality Rate by Day 28
Time frame: Up to Day 28
Clinical Status on 7-Category Ordinal Scale at Day 28
Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</=2 liters supplemental oxygen) 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death
Time frame: Day 28
Percentage of Participants With Adverse Events
Time frame: Up to Day 60
| Milestone | Tocilizumab | Placebo |
|---|---|---|
| Started | 249 | 128 |
| Completed | 225 | 115 |
| Not completed | 24 | 13 |
| Withdrew: Death | 24 | 11 |
| Withdrew: Transferred to a different facility for care | 0 | 2 |
Cumulative proportion is measured as a percentage of participants meeting the endpoint.
| Percentage of Participants | Tocilizumab | Placebo |
|---|---|---|
| Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 | 12.04 (8.52 to 16.86) | 19.26 (13.34 to 27.36) |
| Days | Tocilizumab | Placebo |
|---|---|---|
| Time to Hospital Discharge or "Ready for Discharge" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or >/= 2 Liters (L) Supplemental Oxygen) | 6.0 (6.0 to 7.0) | 7.5 (7.0 to 9.0) |
Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</=2 liters supplemental oxygen) 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death
| Days | Tocilizumab | Placebo |
|---|---|---|
| Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status | 6.0 (6.0 to 7.0) | 7.0 (6.0 to 9.0) |
| Days | Tocilizumab | Placebo |
|---|---|---|
| Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (Whichever Occurred First) | NA (NA to NA) | NA (NA to NA) |
| Percentage of Participants | Tocilizumab | Placebo |
|---|---|---|
| Mortality Rate by Day 28 | 10.4 (7.2 to 14.9) | 8.6 (4.9 to 14.7) |
Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</=2 liters supplemental oxygen) 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death
| Percentage of participants | Tocilizumab | Placebo |
|---|---|---|
| 1 | 85.9 | 82.8 |
| 2 | 0.4 | 1.6 |
| 3 | 2.0 | 0.8 |
| 4 | 0.4 | 0.8 |
| 5 | 0.8 | 3.9 |
| 6 | 0 | 1.6 |
| 7 | 10.4 | 8.6 |
| Percentage of participants | Tocilizumab | Placebo |
|---|---|---|
| Percentage of Participants With Adverse Events | 50.8 | 52.8 |
Collected over Up to Day 60. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab | 29/250 (11.6%) | 38/250 (15.2%) | 28/250 (11.2%) |
| Placebo | 15/127 (11.8%) | 25/127 (19.7%) | 8/127 (6.3%) |
| Event | Tocilizumab | Placebo |
|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 2/250 | 3/127 |
| PneumoniaInfections and infestations | 0/250 | 3/127 |
| Septic shockInfections and infestations | 5/250 | 3/127 |
| Acute kidney injuryRenal and urinary disorders | 1/250 | 3/127 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 4/250 | 3/127 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 5/250 | 1/127 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 4/250 | 2/127 |
| Pneumonia bacterialInfections and infestations | 0/250 | 2/127 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/250 | 1/127 |
| Cardiac arrestCardiac disorders | 2/250 | 1/127 |
| Event | Tocilizumab | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 16/250 | 4/127 |
| AnxietyPsychiatric disorders | 15/250 | 4/127 |
mITT population = all randomized participants who received study treatment, grouped according to the treatment assigned at randomization. Participants not receiving study treatment were excluded from analyses.
| Age, Continuous(Years) | Tocilizumab | Placebo | Total |
|---|---|---|---|
| Mean | 56.0 ± 14.3 | 55.6 ± 14.9 | 55.9 ± 14.4 |
| Sex: Female, Male(Participants) | Tocilizumab | Placebo | Total |
|---|---|---|---|
| Female | 99 | 55 | 154 |
| Male | 150 | 73 | 223 |
| Ethnicity (NIH/OMB)(Participants) | Tocilizumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 143 | 68 | 211 |
| Not Hispanic or Latino | 106 | 60 | 166 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Tocilizumab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 52 | 25 | 77 |
| Asian | 5 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 35 | 22 | 57 |
| White | 134 | 65 | 199 |
| More than one race | 4 | 2 | 6 |
| Unknown or Not Reported | 19 | 12 | 31 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from May 2020 to primary completion in Aug 2020, 3 months.
Results were first posted in Sep 2021, 1 year 1 month after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 3 months is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab